Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation
- PMID: 28030619
- PMCID: PMC5193350
- DOI: 10.1371/journal.pone.0168860
Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation
Abstract
Introduction and purpose: Propidium monoazide (PMA)-pretreatment has increasingly been applied to remove the bias from dead or damaged cell artefacts, which could impact the microbiota analysis by high-throughput sequencing. Our study aimed to determine whether a PMA-pretreatment coupled with high-throughput sequencing analysis provides a different picture of the airway mycobiome and bacteriome. VSports手机版.
Results and discussion: We compared deep-sequencing data of mycobiota and microbiota of 15 sputum samples from 5 cystic fibrosis (CF) patients with and without prior PMA-treatment of the DNA-extracts. PMA-pretreatment had no significant effect on the entire and abundant bacterial community (genera expressed as operational taxonomic units (OTUs) with a relative abundance greater than or equal to 1%), but caused a significant difference in the intermediate community (less than 1%) when analyzing the alpha biodiversity Simpson index (p = 0. 03). Regarding PMA impact on the airway mycobiota evaluated for the first time here; no significant differences in alpha diversity indexes between PMA-treated and untreated samples were observed V体育安卓版. Regarding beta diversity analysis, the intermediate communities also differed more dramatically than the total and abundant ones when studying both mycobiome and bacteriome. Our results showed that only the intermediate (or low abundance) population diversity is impacted by PMA-treatment, and therefore that abundant taxa are mostly viable during acute exacerbation in CF. Given such a cumbersome protocol (PMA-pretreatment coupled with high-throughput sequencing), we discuss its potential interest within the follow-up of CF patients. Further studies using PMA-pretreatment are warranted to improve our "omic" knowledge of the CF airways. .
Conflict of interest statement (V体育安卓版)
Sophie Merlin, Alexandre Loywick and Christophe Audebert are employed by GenesDiffusion. There are no patents, products in development or marketed products to declare in relation with our study. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors V体育ios版.
Figures





References
MeSH terms
- "V体育官网入口" Actions
- VSports - Actions
- "VSports最新版本" Actions
- VSports注册入口 - Actions
- Actions (V体育官网入口)
- "VSports注册入口" Actions
- V体育安卓版 - Actions
- Actions (V体育官网入口)
- "VSports最新版本" Actions
- Actions (V体育安卓版)
Substances
- VSports在线直播 - Actions
- V体育2025版 - Actions
"V体育平台登录" LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical